Steglujan (ertugliflozin/sitagliptin) / Pfizer, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 0 Diseases   0 Trials   0 Trials   43 News 
  • ||||||||||  Steglujan (ertugliflozin/sitagliptin) / Pfizer, Merck (MSD)
    A Case of MODY Due to a Rare Activating Variant in the ABCC8 Gene (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_1531;    
    Activating mutations of ABCC8 gene are infrequent genetic causes of diabetes in adults. Sequencing of the ABCC8 gene should be considered in select adult patients, as diagnosis can guide management decisions.
  • ||||||||||  Journal:  Drugs for type 2 diabetes. (Pubmed Central) -  Nov 18, 2022   
    Not yet recruiting --> Recruiting No abstract available
  • ||||||||||  Steglujan (ertugliflozin/sitagliptin) / Pfizer, Merck (MSD), Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    Review, Journal:  Review of pharmaceutical and therapeutic approaches for type 2 diabetes and related disorders. (Pubmed Central) -  Aug 24, 2022   
    In the present review article, we have made an attempt to explore the risk factors, Genes, and diseases associated with T2D, therapeutic approaches in T2D, the influences of drugs such as Dapagliflozin, Metformin, Acarbose, Januvia (Sitagliptin), and Ertugliflozin on T2D in clinical trials and animal model studies. Research in clinical trials has promising results that support the role of these drug approaches in T2D prophylaxis and ameliorate safety even though additional clinical research is still obligatory.
  • ||||||||||  Steglatro (ertugliflozin) / Pfizer, Merck (MSD)
    Clinical, Journal:  Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus. (Pubmed Central) -  May 11, 2021   
    P3
    In a placebo-controlled study, when initiated in combination with sitagliptin, the placebo-corrected change from baseline in HbA1c at week 26 for ertugliflozin 5 mg/sitagliptin and ertugliflozin 15 mg/sitagliptin was -1.3 and -1.6%, respectively...: Ertugliflozin, administered as a single agent or as combination with sitagliptin, improved HbA1c, BW, and SBP. Ertugliflozin was generally well-tolerated in Hispanic/Latino patients with T2DM.
  • ||||||||||  metformin / Generic mfg.
    Journal:  Ertugliflozin alone and in fixed-dose combinations : «pass of three» (Pubmed Central) -  Sep 18, 2020   
    This SGLT2i is also available in fixed-dose combinations, ertugliflozin-metformin and ertugliflozin-sitagliptin. The three presentations offer a greater flexibility to the practitioner to optimize therapeutic choices for a complex disease where the treatment should be individualized according to the patient profile.
  • ||||||||||  Review, Journal:  Drugs for type 2 diabetes. (Pubmed Central) -  Dec 22, 2019   
    The lack of clinically meaningful pharmacokinetic interactions demonstrates that ertugliflozin can be coadministered safely with sitagliptin, metformin, glimepiride, or simvastatin without any need for dose adjustment. No abstract available
  • ||||||||||  Steglujan (ertugliflozin/sitagliptin) / Pfizer, Merck (MSD)
    Preclinical, Journal:  UPLC-MS/MS method for the quantification of ertugliflozin and sitagliptin in rat plasma. (Pubmed Central) -  Nov 19, 2019   
    Matrix effect, extraction recovery, and stability data were in line with the stipulated FDA guidelines for validating a bioanalytical method. The validity of the designed method was confirmed through the pharmacokinetic experiments.
  • ||||||||||  Steglujan (ertugliflozin/sitagliptin) / Pfizer, Merck (MSD)
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  Approaches To Therapy Escalation In T2D (clinicaltrials.gov) -  Sep 26, 2019   
    P4,  N=0, Withdrawn, 
    The validity of the designed method was confirmed through the pharmacokinetic experiments. Not yet recruiting --> Withdrawn | Trial primary completion date: Mar 2020 --> Sep 2019 | N=600 --> 0 | Trial completion date: Jul 2020 --> Sep 2019
  • ||||||||||  metformin / generics
    Journal:  Ertugliflozin for the treatment of type 2 diabetes. (Pubmed Central) -  May 21, 2019   
    It also has a longer half-life (16.6 hours) than presently available gliflozins, which translates into single daily dosing and dose reduction allowing for patient compliance. This review will focus on the preclinical pharmacology, pharmacokinetics, clinical efficacy and safety of ertugliflozin.
  • ||||||||||  Steglujan (ertugliflozin/sitagliptin) / Pfizer, Merck (MSD), Segluromet (ertugliflozin/metformin) / Pfizer, Merck (MSD)
    Review, Journal:  Ertugliflozin for type 2 diabetes. (Pubmed Central) -  May 4, 2019   
    This review will focus on the preclinical pharmacology, pharmacokinetics, clinical efficacy and safety of ertugliflozin. No abstract available
  • ||||||||||  metformin / generics
    Clinical, Journal:  Ertugliflozin: First Global Approval. (Pubmed Central) -  Apr 7, 2019   
    These products have also received a positive opinion from the EU Committee for Medicinal Products for Human Use (CHMP). This article summarizes the milestones in the development of ertugliflozin leading to its first approval for T2DM.
  • ||||||||||  Steglujan (ertugliflozin/sitagliptin) / Pfizer, Merck (MSD)
    New P4 trial:  Approaches To Therapy Escalation In T2D (clinicaltrials.gov) -  Jan 22, 2019   
    P4,  N=600, Not yet recruiting,